---
title: "Biotech & Healthtech Funding May–June 2026: ADCs, Immune Mapping, and AI Care"
description: "Anagram Therapeutics, Ona Therapeutics, IMU Biosciences, and Garner Health show biotech and healthtech capital in 2026 favoring validated science and AI-enabled care."
date: 2026-06-10T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "healthtech", "market-analysis"]
source: https://venturecapitaltracker.com/2026-biotech-healthtech-funding-may-june-2026
---

# Biotech & Healthtech Funding May–June 2026: ADCs, Immune Mapping, and AI Care

> Anagram Therapeutics, Ona Therapeutics, IMU Biosciences, and Garner Health show biotech and healthtech capital in 2026 favoring validated science and AI-enabled care.

Biotech and healthtech in May–June 2026 followed the same discipline reshaping the rest of venture: **fund validated science and measurable outcomes**, not platform promises. The winners pair real clinical data with credible commercial paths.

### The deal sheet
| Company | Region | Amount | Focus |
|---------|--------|--------|-------|
| **Anagram Therapeutics** | U.S. | $250M | Therapeutics |
| **Garner Health** | U.S. | $100M Series E | Healthcare data ($2.74B val) |
| **Ona Therapeutics** | Spain | $86.6M Series B | Antibody-drug conjugates |
| **IMU Biosciences** | UK | $53M+ Series A | Immune-system mapping |
| **Semble** | UK | £30M Series C | Health tech |

### Three themes
1. **Hard science is fundable.** Ona Therapeutics' oversubscribed $86.6M targets first-in-class ADCs for treatment-resistant cancers — exactly the validated, differentiated science investors will still pay for.
2. **Data infrastructure for care.** Garner Health's $100M Series E (Index Ventures, $2.74B valuation) backs a provider-finding platform — healthcare data as a durable, defensible layer.
3. **AI plus clinical rigor.** IMU Biosciences' immune-decoding platform and Europe's health-tech rounds (Semble) reflect demand for tools that improve outcomes or reduce cost with measurable evidence.

### The discipline that defines the cohort
Across geographies, the fundable healthcare company shows **clinical validation, regulatory pathways, or cost evidence** — not generic wellness. Capital is patient but selective, rewarding depth.

### Practical takeaway (operator + investor)
Healthcare founders should **lead with clinical or economic proof** — trial data, abstraction accuracy, or cost savings. For investors, the durable opportunities sit in validated therapeutics, care-delivery data infrastructure, and AI tools with demonstrated outcomes.

### Sources
1. PipelineRoad / Crunchbase (Anagram Therapeutics $250M): https://pipelineroad.com/news/20260508-top-10-biggest-funding-rounds-this-week-in-ai-and-tech
2. Crunchbase News (Garner Health $100M Series E): https://news.crunchbase.com/ai/biggest-funding-rounds-ai-anthropic-65b-dominates/
3. Startuprise (Ona Therapeutics, IMU Biosciences, Semble): https://startuprise.co.uk/top-funding-wrap-of-the-week-01-june-05-june-2026/